PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Hematology, CHU Rennes, University of Rennes, INSERM U1236, Rennes, France; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: roch.houot@chu-rennes.fr.\', \'Department of Medical Oncology, Stanford University School of Medicine, Stanford, CA, USA.\', \'Department of Hematology, CHU Montpellier University Hospitality, University of Montpellier, Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, Montpellier, France.\', \'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0959-8049(20)30350-610.1016/j.ejca.2020.06.017
?:hasPublicationType
?:journal
  • European journal of cancer (Oxford, England : 1990)
is ?:pmid of
?:pmid
?:pmid
  • 32619884
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all